Exact Sciences could benefit from Trump-era tariffs, with Jefferies reiterating a Buy rating on the company.
1 report, 1 independent
Updated Aug 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Exact Sciences could benefit from Trump-era tariffs, with Jefferies reiterating a Buy rating on the company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Exact Sciences
American company in Madison, United States
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- Trump's tariffs spooked markets, specifically impacting MSCI.
- Elastic benefits from the trend of onshoring and tariffs associated with the Trump administration.
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.
- Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
Coverage
Newest first; wire copies grouped- Insider MonkeyJefferies Reiterates a Buy Rating on Exact Sciences Corporation (EXAS) Exact Sciences Corporation (NASDAQ:EXAS) is one of the best strong buy growth stocks to buy now. On August 21, Jefferies analyst